SEC Form 4 · accession 0001140361-16-058284
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Mar 15, 2016
Accepted (ET)
Mar 17, 2016 · 5:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 15, 2016 | A | 60,710 | $0.00 | A | 392,221 | D | |
| Common Stock | holding | — | — | — | 25,758 | I | Shares held by Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) Common StockF2 | $83.43 | Mar 15, 2016 | A | 136,050 | A | Mar 15, 2017 | Mar 14, 2026 | Common Stock | 136,050 | 136,050 | D |
Explanation of responses
- F1Restricted stock units granted on March 15, 2016. Price not applicable.
- F2Option grant vests 12/48th on March 15, 2017 and 1/48th on the 15th day of each month thereafter.